Drug firm Alembic Pharmaceuticals on Thursday said its joint venture firm Aleor Dermaceuticals has got approval from the the US health regulator for Desonide Ointment.
Desonide Ointment, 0.05 per cent, is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses, Alembic Pharmaceuticals sad in a BSE filing.
The company said its joint venture Aleor Dermaceuticals has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Desonide ointment 0.05 per cent.
Citing IQVIA data, the company said the approved ANDA is therapeutically equivalent to the reference listed drug product, Desonide Ointment, 0.05, of Perrigo New York, Inc. It has an estimated market size of USD 13 million for 12 months ending December 2018.
Alembic has a cumulative total of 105 ANDA approvals (93 final approvals and 12 tentative approvals) from the USFDA.
Shares of the company were trading 1.27 per cent up at Rs 544 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app